Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

Summary

This is an open label, randomized phase II trial. Eligible subjects will be randomized in a 1:1 ratio and stratified for known prognostics variables to one of two first-line medication treatment arms. Once disease progression has been documented, and following a required inter-line washout period, subjects will receive either second-line medication treatment or discontinue treatment, per discretion of treating investigator.

Timeline

Start

2017-05-23

Primary completion

2018-12

Completion

2020-12

Outcome

Outcome not reported

Stopped: “Principal investigator left lead institution and efforts to open the protocol at another institution were not successful.”

Drugs

Indications